ga

Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.

CADTH » Search All Products » Optimal Use » Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses » Background

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Background

Schizophrenia affects up to 1% of the Canadian population; it is often diagnosed in persons in the 16 to 30 years age group. The total financial burden of schizophrenia in Canada was estimated to be C$6.85 billion in 2004.

Newer antipsychotic drugs (also known as atypical antipsychotics) are commonly used to treat this condition. In Canada, the following atypical antipsychotic drugs are available: aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. Two other atypical antipsychotic agents were recently approved in the United States: asenapine and iloperidone. The use of these medications at doses higher than usually recommended is increasing. In addition, the proportion of patients treated with more than one atypical antipsychotic agent has increased in recent years.

By reviewing the evidence, developing optimal use recommendations, and providing supporting intervention tools, CADTH will give health professionals, policy-makers, and patients the evidence-based resources they need to make sound decisions in this therapeutic area.